Emergent BioSolutions Inc
NYSE:EBS

  • LAST PRICE
    9.3500
  • TODAY'S CHANGE (%)
    0.4100 (4.5861%)
  • Bid / Lots
    9.2100/ 5
  • Ask / Lots
    9.3500/ 5
  • Open / Previous Close
    9.0400 / 8.9400
  • Day Range
    8.8600
    9.5700
  • 52 Week Range
    1.4200
    15.1000
  • Volume
    1,634,415

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 2, 2024

      Show headlines and story abstract

    • 8:00AM ET on Wednesday Oct 02, 2024 by MT Newswires
      Companies Mentioned: EBS
      08:00 AM EDT, 10/02/2024 (MT Newswires) -- Emergent Biosolutions (EBS) said Wednesday it entered into a new credit agreement for an asset-based revolving loan facility, effective Sept. 30, with Wells Fargo Bank as administrative agent. The credit ag...

    • 7:30AM ET on Wednesday Oct 02, 2024 by Dow Jones
      Companies Mentioned: EBS

      Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

      GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an asset-based revolving loan facility (ABL) with the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent. The credit agreement provides for revolving loan commitments in an aggregate principal amount up to $100 million (availability is based on a borrowing base set forth therein) with a fixed maturity date of September 30, 2029, subject to early maturity triggers based on the maturity of its other material indebtedness. The new credit facility brings additional liquidity to support Emergent's multi-year transformation plan. As of September 30, 2024, Emergent had a cash balance of approximately $150 million and undrawn access to $100 million under the ABL.

    • 7:30AM ET on Wednesday Oct 02, 2024 by Dow Jones
      Companies Mentioned: EBS

      Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

      GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an asset-based revolving loan facility (ABL) with the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent. The credit agreement provides for revolving loan commitments in an aggregate principal amount up to $100 million (availability is based on a borrowing base set forth therein) with a fixed maturity date of September 30, 2029, subject to early maturity triggers based on the maturity of its other material indebtedness. The new credit facility brings additional liquidity to support Emergent's multi-year transformation plan. As of September 30, 2024, Emergent had a cash balance of approximately $150 million and undrawn access to $100 million under the ABL.

  • Sep 26, 2024

Peers Headlines